Recherches "plusieurs pathologies"
EXPRESS
Low level of genomic alteration to predict exceptional and unexpected response to targeted thÚrapies in patients with solid tumors.;EXPRESS : EXcePtional RESponSe
Paris
CHRISTOPHE LE TOURNEAU
Sein métastatique RH+
COMPLEEMENT-1
An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease.
Paris, Saint-Cloud
PAUL-HENRI COTTU, FLORENCE LEREBOURS
Gynécologie - Col utérus
NiCOL (IC 2016-08)
A phase-I study of nivolumab in association with radiotherapy and cisplatin in locally advanced cervical cancers followed by adjuvant nivolumab for up to 6 months
Paris, Saint-Cloud
MANUEL RODRIGUES, CORALINE DUBOT
Sein métastatique RH+
PADA-1
Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HTdriven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients.
Paris, Saint-Cloud
FRANCOIS-CLEMENT BIDARD, CORALINE DUBOT
Sein métastatique RH+
SAFIR-TOR
Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women.
Paris, Saint-Cloud
PAUL-HENRI COTTU
Gynécologie - Endomètre
ENDOLA
A Phase I/II Trial to Assess the Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Recurrent Advanced/Metastatic Endometrial Cancer Patients
Paris
MANUEL RODRIGUES
Recherches "plusieurs pathologies"
CA209-848
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Paris
EMANUELA ROMANO